Business Context and Reporting Period
This Form 8-K Current Report was filed by Pliant Therapeutics, Inc. on July 13, 2026, covering events that occurred on July 9, 2026. The filing details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of new independent directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its authorized size from seven to nine members.
- New Appointments: Robert Iannone, M.D., M.S.C.E. was appointed as a Class I director, and Flavia Borellini, Ph.D. was appointed as a Class II director.
- Committee Assignments: Dr. Iannone was appointed to the Research and Development (R&D) Committee, and Dr. Borellini was appointed as Chairperson of the R&D Committee.
- Independence: Both new directors were determined to be independent under SEC and Nasdaq rules.
Compensation and Governance Details
The new directors will participate in the Company's standard non-employee director compensation arrangements as described in the 2026 Definitive Proxy Statement. Specific terms include:
- Annual Retainers:
- Base Retainer: $40,000 per year for both directors (pro-rated for partial periods).
- R&D Committee Member (Dr. Iannone): Additional $7,500 per year.
- R&D Committee Chair (Dr. Borellini): Additional $15,000 per year.
- Equity Grants: Each director received an option to purchase 60,000 shares of common stock on the Effective Date. These options vest in substantially equal monthly installments over three years, contingent on continuous service.
- Indemnification: The Company entered into standard indemnification agreements with both directors.
Investor Verification Checklist
- Verify the full text of the 2026 Definitive Proxy Statement filed on April 22, 2026, to review the complete director compensation structure.
- Confirm the vesting schedule and exercise price of the 60,000 share options granted to the new directors.
- Review the Company's subsequent filings to monitor the impact of the expanded Board on strategic R&D decisions.